Home » Newsletters » BioWorld Science

BioWorld Science

June 3, 2005

View Archived Issues

Questioning creates knowledge: the Summer/Fall 2005 issue of Prous Science News now available

BioInvent set to begin U.K. study of BI-201 for HIV

Antisense Therapeutics updates development status

Astex receives CTA approval for AT-7519 and selects new drug candidates

Bionomics to acquire Iliad Chemicals

Treatment begins in phase IIb colorectal cancer study of CoFactor

Centocor extends enrollment for phase II Crohn's disease study of CNTO-1275

Enrollment progresses well in phase III FavId study in NHL

Approvable letter for nebivolol

Arena tests a new 5-HT2C receptor agonist for obesity treatment

Novel chemokine CXCR2 antagonist effective against lung neutrophilia in mice

Better effects of DPI-221 than morphine or oxybutynin on micturition in rats

VT-111/ciclosporin combination therapy prevents cardiac transplant rejection

Mechanisms underlying of PG-490-88/FK-506 renal allograft survival

A selective ETA antagonist prevents pancreatic I/R injury

Therapeutic potential for JNJ-7777120 in allergic airway disease

Preclinical studies demonstrate that R-406 may be a potential asthma therapy

ONO-6126: a treatment for COPD

Prous Science webcasts James D. Watson conference

ACR-16 recommended for orphan drug status for Huntington's disease

COMP recommends orphan drug status for 1D09C3 for Hodgkin's lymphoma

Inspire submits NDA amendment for diquafosol for dry eye

Not approvable letter for Risperdal for psychosis of Alzheimer's disease

Allergan receives written FDA response for oral tazarotene NDA

Novel treatments for respiratory and allergic disorders disclosed in recent patents

Canadian approval of Glumetza for type 2 diabetes

Daiichi and Sankyo sign definitive agreement on business integration

Novel antiinflammatory agents imparted in recent patent literature

A curcumin/quercetin combination improves early kidney graft function

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...